Articles

PP42 Th17 impact on xenogeneic graft-versus-host disease

BJH - 2018, issue Abstract Book BHS, february 2018

L. Delens , G. Ehx , L. Vrancken , G. Fransolet , C. Grégoire MD, M. Hannon , S. Dubois , C. Daulne , Y. Beguin MD, PhD, prof. F. Baron , S. Servais MD, PhD

Read more

PP71 Impact of Tofacitinib on xenogeneic graft versus host disease

BJH - volume 8, issue Abstract Book BHS, february 2017

M. Hannon , C. Grégoire MD, J. Muller MSc, G. Fransolet , L. Delens , Y. Beguin MD, PhD, G. Ehx , prof. F. Baron

Read more

Multipotent mesenchymal stromal cell therapy for steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation

BJH - volume 7, issue 6, december 2016

S. Servais MD, PhD, C. Grégoire MD, prof. F. Baron , E. Willems MD, PhD, A. Briquet PhD, E. Baudoux MD, O. Delloye PhD, O. Giet PhD, C. Lechanteur PhD, Y. Beguin MD, PhD

Summary

Steroid-refractory acute graft-versus-host disease is a severe complication after allogeneic stem cell transplantation. So far, its treatment remains very challenging since the current therapies do not offer significant benefits. Among the most recent approaches, multipotent mesenchymal stromal cell-based therapy has attracted great interest over the past decade. Here, we briefly reviewed the current knowledges about the immunomodulatory properties of multipotent mesenchymal stromal cells as well as results of preclinical and clinical studies having assessed their efficacy to modulate steroid-refractory acute graft-versus-host disease.

(BELG J HEMATOL 2016;7(6):229–35)

Read more

PP3.2 Umbilical cord mesenchymal stromal cells are superior to bone marrow and adipose tissue-derived mesenchymal stromal cells for the treatment of xenogeneic graft-versus-host disease in mice

BJH - volume 7, issue Abstract Book BHS, january 2016

C. Grégoire MD, Y. Beguin MD, PhD, M. Hannon , S. Dubois , B. Baudoux , A. Briquet PhD, C. Lechanteur PhD, G. Ehx , prof. F. Baron

Read more